Home › Funds › KINGDON CAPITAL MANAGEMENT, L.L.C. › SNDX

KINGDON CAPITAL MANAGEMENT, L.L.C. position in SNDX

SYNDAX PHARMACEUTICALS INC · Health Care

KINGDON CAPITAL MANAGEMENT, L.L.C. reported holding 2,500,000 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$54.6M, representing 6.00% of its reported portfolio and ranking #2 among its reported holdings. KINGDON CAPITAL MANAGEMENT, L.L.C. has disclosed SNDX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)2.50M sh
Reported value held$54.65M
Portfolio Weight6.00%
First reportedQ4 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How KINGDON CAPITAL MANAGEMENT, L.L.C.'s SNDX position evolved

KINGDON CAPITAL MANAGEMENT, L.L.C. first disclosed a stake in SNDX in Q4 2023 at 746,293 shares (US$16.1M). The position peaked in Q1 2026 at 2,500,000 shares, worth US$58.4M. Across 11 filings, KINGDON CAPITAL MANAGEMENT, L.L.C. increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 2,500,000 shares valued at US$54.6M. Notable position changes include a 100% increase in Q4 2024 (shares fell 7% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 746.29K $16.13M New
Q1 2024 894.99K $21.30M Add
Q2 2024 894.99K $18.37M Hold
Q3 2024 1.00M $19.25M Add
Q4 2024 2.00M $26.44M Add
Q1 2025 2.00M $24.57M Hold
Q2 2025 2.10M $19.67M Add
Q3 2025 2.50M $38.46M Add
Q4 2025 2.35M $49.37M Reduce
Q1 2026 2.50M $58.40M Add
Q2 2026 2.50M $54.65M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SNDX and 13F data

SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 42 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SNDX

All SNDX fund holders →

FAQ

How long has KINGDON CAPITAL MANAGEMENT, L.L.C. held SNDX?

KINGDON CAPITAL MANAGEMENT, L.L.C. has disclosed SNDX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is KINGDON CAPITAL MANAGEMENT, L.L.C.'s current position in SNDX?

As of Q2 2026, KINGDON CAPITAL MANAGEMENT, L.L.C. holds 2.50M shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $54.65M, representing 6.00% of its reported portfolio and ranking #2.

Has KINGDON CAPITAL MANAGEMENT, L.L.C. been buying or selling SNDX?

In the latest 13F filing (Q2 2026), KINGDON CAPITAL MANAGEMENT, L.L.C. held unchanged its position in SNDX. The position peaked in Q1 2026 at 2.50M shares.

Which other funds hold SNDX?

Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.